Cetera Investment Advisers
ITRM

Cetera Investment Advisers’s Iterum Therapeutics ITRM Stock Holding History

Cetera Investment Advisers’s Portfolio ITRM Stock Details ITRM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-1,000
Closed -$15K – 1657
2020
Q4 		$15K Buy
+1,000
New +$11.7K ﹤0.01% 1552

Other funds holding ITRM

CPX
Canaan Partners X Menlo Park, California $74.7M AUM 151.56% 1-Year Est. Return
FM
Frazier Management Seattle, Washington $1.12M AUM 151.58% 1-Year Est. Return
NLVP
New Leaf Venture Partners New York $43M AUM 25.55% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
HF
HRT Financial New York $54.8B AUM 81.03% 1-Year Est. Return
FNBT
FineMark National Bank & Trust Fort Myers, Florida $3.2B AUM 18.28% 1-Year Est. Return
IA
Insight Advisors Newtown, Pennsylvania $567M AUM 25.52% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
VF
Virtu Financial New York $3.18B AUM 65.92% 1-Year Est. Return

Cetera Investment Advisers's ITRM Position: Q1 2021 in Review

Cetera Investment Advisers sold out of Iterum Therapeutics (ITRM) in Q1 2021, closing a stake of 1,000 shares — an estimated $15K sold.

Cetera Investment Advisers first reported a position in ITRM in Q4 2020 and held it in 1 quarter. The position peaked at $15K in Q4 2020. 50 funds tracked by Wall St. Rank hold ITRM as of Q1 2021.

  • Cetera Investment Advisers reported no remaining Iterum Therapeutics position as of Q1 2021 after selling out during the quarter.
  • Cetera Investment Advisers sold 1,000 Iterum Therapeutics shares in Q1 2021, an estimated $15K.
  • Cetera Investment Advisers first reported a position in Iterum Therapeutics in Q4 2020 and held it in 1 quarter.
  • Cetera Investment Advisers's Iterum Therapeutics position peaked at $15K in Q4 2020.
  • 50 funds tracked by Wall St. Rank held Iterum Therapeutics as of Q1 2021.

Based on Cetera Investment Advisers's 13F filing for Q1 2021, filed 17 May 2021.